D. Natale

发表

Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer

R. Todeschini, M. Pirovano, S. Barni, 2016, Tumori.

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer

I. Vergote, S. Pignata, J. Bryce, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.

I. Vergote, S. Pignata, J. Bryce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients

F. Angrilli, C. Broglia, S. Sacchi, 2007, Leukemia & lymphoma.

Juvenile chronic myelogenous leukemia: report of the Italian Registry. Associazione Italiana di Ematologia Oncologia Pediatrica (AIEOP).

A. Pession, R. Miniero, M. Pillon, 1993, Haematologica.

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

S. Pignata, G. Signoriello, G. Scambia, 2006, BMC Cancer.

Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer

A. Russo, V. Formica, M. Roselli, 2017, Oncotarget.

Capecitabine plus oxaliplatin for the first‐line treatment of elderly patients with metastatic colorectal carcinoma

A. Gambardella, V. Lorusso, S. Tafuto, 2005, Cancer.

Castleman's disease

A. Riccio, G. Pettinato, A. Puzziello, 2001, Annals of the rheumatic diseases.

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401

G. Filippelli, B. Massidda, P. Comella, 2009, Journal of Cancer Research and Clinical Oncology.

Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).

A. Gambardella, M. Ghiani, M. Roselli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

A. Brandes, S. Pignata, M. Valerio, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.

V. Lorusso, M. Roselli, G. Filippelli, 2005, Clinical colorectal cancer.

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.

V. Lorusso, M. Roselli, G. Filippelli, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw.

C. Broglia, S. Sacchi, G. Quarta, 2005 .

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study

S. Tafuto, B. Massidda, P. Comella, 2005, Cancer Chemotherapy and Pharmacology.

A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.

A. Gambardella, V. Lorusso, S. Tafuto, 2005, Critical reviews in oncology/hematology.

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC

R. Franco, G. Chiappetta, S. Pignata, 2016, Oncotarget.

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.

S. Barni, R. Labianca, D. Amadori, 2021, European journal of cancer.

Serum Levels of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in a Group of Patients with Systemic Sclerosis

A. Riccio, L. Postiglione, S. Montagnani, 1996 .

The lack of correlation between the positivity of anti-platelet antibodies and the presence of thrombocytopenia in course of HIV infection.

A. Riccio, A. Chirianni, G. Fratellanza, 1993, Bollettino della Societa italiana di biologia sperimentale.

Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.

C. Sandomenico, G. Filippelli, S. Tafuto, 2011, Clinical colorectal cancer.

Oxaliplatin (OXA) plus folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus (OXAFAFU) versus irinotecan (IRI) plus FA and FU i.v. bolus (IRIFAFU) in advanced colorectal carcinoma (ACC): Activity and toxicity results of the SICOG 0103 randomized trial.

G. Filippelli, S. Tafuto, F. De Vita, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.